# Kirsten Fischer

Source: https://onco.cc/people/kirsten-fischer/  
OnCo record `kirsten-fischer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment.

## Summary

Kirsten Fischer was principal investigator of CLL14, the German CLL Study Group trial showing twelve months of venetoclax plus obinutuzumab produces deep, MRD-negative remissions and superior progression-free survival compared with chlorambucil-obinutuzumab in unfit patients with untreated CLL, creating the fixed-duration treatment paradigm. She coordinated the CLL8 and CLL10 chemoimmunotherapy trials and leads long-term follow-up of CLL14.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; venetoclax; fixed-duration
- Role: Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne
- Specialisms: Chronic lymphocytic leukaemia; Fixed-duration therapy; Venetoclax combinations; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/)
- trials: [CLL14](https://onco.cc/trials/cll14/)
- key papers: [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/)

---
JSON: https://onco.cc/api/v1/entities/kirsten-fischer.json